A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Chicago
Centre Hospitalier Universitaire Vaudois
Astellas Pharma Inc
Astellas Pharma Inc
Memorial Sloan Kettering Cancer Center
University of Utah
Providence Health & Services
Sanofi
Sanofi
University of Pennsylvania
Haukeland University Hospital
Washington University School of Medicine
Boehringer Ingelheim
Eli Lilly and Company
Sunesis Pharmaceuticals
Rockefeller University
XOMA (US) LLC